Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-017532

CHIEF FINANCIAL OFFICER sold 3,000 shares at $22.55 ($67,655)

  • CHIEF FINANCIAL OFFICER acquired 3,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2025-06-13 Option exercise 10b5-1 +3,000 $2.48 $7,440 26,000 D: show line 1 in the form
Hohl Benjamin CHIEF FINANCIAL OFFICER 2025-06-13 Sale 10b5-1 −3,000 $22.55 $67,655 23,000 D: show line 2 in the form
Open-market sales · 3,000 sh · avg $22.55 · $67,655

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2025-06-13 Option exercise · Stock Option (right to buy) 10b5-1 −3,000 119,056 D: show line 3 in the form
Loading xslF345X05/form4-06172025_080605.xml…